Regeneron的股票目标被JP摩根公司降低,尽管该公司击败了对Q4收入的估计。 Regeneron's stock target was lowered by JPMorgan, despite the company beating Q4 earnings estimates.

Regenenron制药公司(NASDAQ:REGN)看到JP摩根将价格目标从1 100美元降低到1 000美元,同时保持超重评级。 Regeneron Pharmaceuticals (NASDAQ: REGN) saw JPMorgan lower its price target from $1,100 to $1,000, while maintaining an overweight rating. 该公司报告Q4 EPS为12.07美元,击打估计数为0.86美元。 The company reported a Q4 EPS of $12.07, beating estimates by $0.86. 其市场上限为68.39亿美元,PE比率为16.34, Regeneron以其EYLEA注射而著称,其协商一致目标价格为966.88美元,平均评分为“Moderate Buy”。 With a market cap of $68.39 billion and a PE ratio of 16.34, Regeneron, known for its EYLEA injection, has a consensus target price of $966.88 and an average rating of "Moderate Buy." Leerink Partners最近将其Q1 EPS估计值降至7. 07美元, Leerink Partnrs recently lowered its Q1 EPS estimate to $7.07 but kept a "Strong-Buy" rating.